Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study

被引：35
|
作者：
Motzer, Robert [1 ]
Porta, Camillo [2 ,3 ]
Alekseev, Boris [4 ]
Rha, Sun Young [5 ]
Choueiri, Toni K. [6 ]
Mendez-Vidal, Maria Jose [7 ]
Hong, Sung-Hoo [8 ]
Kapoor, Anil [9 ]
Goh, Jeffrey C. [10 ,11 ]
Eto, Masatoshi [12 ]
Bennett, Lee [13 ]
Wang, Jinyi [13 ]
Pan, Jie Janice [14 ]
Saretsky, Todd L. [15 ]
Perini, Rodolfo F. [15 ]
He, Cixin Steven
Mody, Kalgi [14 ]
Cella, David [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
[2] Univ Bari A Moro, Interdisciplinary Dept Med, Bari, Italy
[3] Univ Pavia, Dept Biomed Sci & Human Oncol, Pavia, Italy
[4] PA Herzen Moscow Oncol Res Inst, Dept Oncourol, Moscow, Russia
[5] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[7] Univ Reina Sofia, Cordoba Hosp, Maimonides Inst Biomed Res, Cordoba, Spain
[8] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea
[9] McMaster Univ, Hamilton, ON, Canada
[10] South Brisbane, ICON Res, Brisbane, Qld, Australia
[11] Queensland Univ Technol, Brisbane, Qld, Australia
[12] Kyushu Univ, Fukuoka, Japan
[13] RTI Hlth Solut, Res Triangle Pk, NC USA
[14] Eisai, Nutley, NJ USA
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 06期
关键词：
EQ-5D;
D O I：
10.1016/S1470-2045(22)00212-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Copyright (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码：768 / 780
页数：13
相关论文
共 50 条
  • [31] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
    Cella, D.
    Pickard, A. S.
    Duh, M. S.
    Guerin, A.
    Mishagina, N.
    Antras, L.
    Neary, M. P.
    McCann, L.
    Hodge, R.
    Sternberg, C. N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) : 311 - 323
  • [33] First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Peng, Libo
    CLINICAL GENITOURINARY CANCER, 2023, 21 (03) : 417e1 - 417e10
  • [34] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
    Haro-Silerio, Jaime Ivan
    Johns, Andrew
    Moussa, Mohammad Jad
    Wang, Mindy
    Wang, Emily
    Kovitz, Craig A.
    Campbell, Matthew T.
    Jonasch, Eric
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
  • [35] Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kulkarni, Amit S.
    Cheng, Ann-Lii
    Bouattour, Mohamed
    Lim, Ho Yeong
    Breder, Valeriy
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen L.
    Daniele, Bruno
    Norquist, Josephine M.
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Finn, Richard S.
    Kudo, Masatoshi
    CANCER, 2021, 127 (06) : 865 - 874
  • [36] Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (CLEAR study)
    Motzer, Robert
    George, Saby
    Merchan, Jaime R.
    Hutson, Thomas E.
    Song, Xun
    Perini, Rodolfo F.
    Xie, Ran
    Bapat, Urmi
    Ebaid, Basant
    Puente, Javier
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 121 - 122
  • [37] Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
    Vaughn, David J.
    Bellmunt, Joaquim
    Fradet, Yves
    Lee, Jae Lyun
    Fong, Lawrence
    Vogelzang, Nicholas J.
    Climent, Miguel A.
    Petrylak, Daniel P.
    Choueiri, Toni K.
    Necchi, Andrea
    Gerritsen, Winald
    Gurney, Howard
    Quinn, David I.
    Culine, Stephane
    Sternberg, Cora N.
    Mai, Yabing
    Li, Haojie
    Perini, Rodolfo F.
    Bajorin, Dean F.
    de Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (16) : 1579 - +
  • [38] Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
    Grunwald, Viktor
    Motzer, Robert J.
    Keizman, Daniel
    Bedke, Jens
    Schmidinger, Manuela
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Cost-effectiveness and budget impact of pembrolizumab plus axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
    Xander, Nicolas S. H.
    Fiets, W. Edward
    Uyl-de Groot, Carin A.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [40] Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study
    Matsubara, Nobuaki
    Naito, Yoichi
    Nakano, Kenji
    Fujiwara, Yutaka
    Ikezawa, Hiroki
    Yusa, Wataru
    Namiki, Masayuki
    Okude, Takashi
    Takahashi, Shunji
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (11) : 922 - 928
12345